A Study to Evaluate Intact FGF23 Performance in Patients with Tumor-induced Osteomalacia (TIO) and X-linked Hypophosphatemia (XLH)


About this study

The purpose of this study is to establish the clinical performance of the Medfrontier Intact FGF23 immunoassay in patients with tumor induced osteomalacia (TIO) and X-linked hypophosphatemia (XLH).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:  

  • Patients with hypophosphatemia or suspected tumor induced osteomalacia (TIO) or suspected or confirmed X-linked hypophosphatemia (XLH).

Exclusion Criteria: 

  • Patients with iron deficiency and chronic kidney disease as these patients might have elevations of FGF23.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Alicia Algeciras-Schimnich, Ph.D.

Open for enrollment

Contact information:

Stephanie Hafner B.S.



More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer